Lapatinib for treatment of advanced or metastasized breast cancer: systematic review

Riera, Rachel; Soárez, Patrícia Coelho de; Puga, Maria Eduarda dos Santos; Ferraz, Marcos Bosi

doi:10.1590/s1516-31802009000500009

Cited by 6 publications

(8 citation statements)

References 26 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All SRs were on gynecological topics: teriparatide for osteoporosis in post-menopausal women (10), lapatinib for advanced or metastasized breast cancer (11), comparative evaluation of digital mammography and film mammography (12), colposcopic triage methods for grade 3 cervical intraepithelial neoplasia (CIN3) after a cytopathological diagnosis of a low-grade squamous intraepithelial lesion (13) and risk of persistent high-grade squamous intraepithelial lesion after an electrosurgical excision with positive margins (14). Three of the reviews focused on treatment (10,11,14), and two focused on diagnosis (12,13). Three of these SRs presented meta-analyses of their results (10,13,14).…”

Section: Resultsmentioning

confidence: 99%

“…The review concluded that the combination of lapatinib plus capecitabine was more effective than capecitabine monotherapy for reducing the risk of cancer progression. However, the authors emphasized the need for more randomized clinical trials to assess the effectiveness of lapatinib alone or in association with other drugs as first- or second-line treatments for advanced breast cancer (11). …”

Section: Resultsmentioning

confidence: 99%

“…Only two SRs (10,12) provided a list of included/excluded studies and clearly stated that duplicate study selection and data extraction had been performed. Only two SRs assessed the quality of included CTs: Riera et al (11) used the Cochrane risk of bias table (9), and Iared et al (12) used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool (18). Finally, only two SRs used an appropriate method to combine studies (12,14).…”

Section: Resultsmentioning

confidence: 99%

“…Authors of SRs should grade the quality of their recommendations and the strength of the evidence presented, which inevitably depend on the quality of the original studies included in the review. Out of the five published reviews, only two (11,13) provided quality assessments of the primary studies, and none mentioned this assessment in their conclusions. Another frequent flaw was the failure to assess publication bias, which was not investigated by any of the five reviews.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Methodological quality of systematic reviews and clinical trials on women's health published in a Brazilian evidence-based health journal

Macedo¹,

Riera²,

Torloni³

2013

Clinics

Self Cite

View full text Add to dashboard Cite

OBJECTIVES:To assess the quality of systematic reviews and clinical trials on women's health recently published in a Brazilian evidence-based health journal.METHOD:All systematic reviews and clinical trials on women's health published in the last five years in the Brazilian Journal of Evidence-based Health were retrieved. Two independent reviewers critically assessed the methodological quality of reviews and trials using AMSTAR and the Cochrane Risk of Bias Table, respectively.RESULTS:Systematic reviews and clinical trials accounted for less than 10% of the 61 original studies on women's health published in the São Paulo Medical Journal over the last five years. All five reviews were considered to be of moderate quality; the worst domains were publication bias and the appropriate use of study quality in formulating conclusions. All three clinical trials were judged to have a high risk of bias. The participant blinding, personnel and outcome assessors and allocation concealment domains had the worst scores.CONCLUSIONS:Most of the systematic reviews and clinical trials on women's health recently published in a Brazilian evidence-based journal are of low to moderate quality. The quality of these types of studies needs improvement.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Methodological quality of systematic reviews and clinical trials on women's health published in a Brazilian evidence-based health journal

Macedo¹,

Riera²,

Torloni³

2013

Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two other previously published meta-analyses have indicated the benefits of using lapatinib plus CET for metastatic and HER-2+ breast cancer 31,35. The present meta-analysis incorporated the results of another published RCT11 and confrmed the benefits of lapatinib plus CET regardless of the treatment line and the efficacy endpoints evaluated, including overall survival.…”

Section: Discussionmentioning

confidence: 60%

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis

Engel¹,

Paladini²,

Clark³

2013

View full text Add to dashboard Cite

BackgroundThis paper reports a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy of lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in human epidermal growth factor receptor 2-overexpressing (HER-2+) locally advanced or metastatic breast cancer.MethodsSeveral databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were progression-free survival and overall survival. The side effects of each treatment were analyzed. The data extracted from the studies were combined by using the hazard ratio or risk ratio with their corresponding 95% confidence interval (CI).ResultsA total of 113 references were identified and screened. The final analysis included four trials comprising 1,073 patients with HER-2+. The overall response rate was higher in patients who received the combination of CET plus lapatinib (risk ratio 0.78; 95% CI 0.71–0.85; P < 0.00001) but with significant heterogeneity (χ2 = 15.61, df = 3; P = 0.001; I2 = 81%). This result remained favorable to the use of lapatinib when a random-effects model analysis was performed (risk ratio 0.76; 95% CI 0.62–0.94; P = 0.01). Progression-free survival was also higher in patients who received CET plus lapatinib (hazard ratio 0.57; 95% CI 0.49–0.66; P < 0.00001) with no heterogeneity detected on this analysis (χ2 = 3.05; df = 3; P = 0.38; I2 = 1%). Overall survival was significantly longer in patients who received CET plus lapatinib (hazard ratio 0.80; 95% CI 0.69–0.92; P = 0.002) without heterogeneity on this analysis (χ2 = 1.26; df = 3; P = 0.74; I2 = 0%). Regarding adverse events and severe toxicities (grade ≥3), the group receiving CET plus lapatinib had higher rates of neutropenia (risk ratio 2.08; 95% CI 1.64–2.62; P < 0.00001), diarrhea (risk ratio 4.82; 95% CI 3.14–7.41; P < 0.00001), and rash (risk ratio 8.03; 95% CI 2.46–26.23; P = 0.0006).ConclusionThe combination of CET plus lapatinib increased the overall response rate, progression-free survival, and overall survival in patients with HER-2+ locally advanced or metastatic breast cancer.

show abstract

Lapatinib Induced Suicidal Death of Human Erythrocytes

Zierle

Bissinger

Egler

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The human epidermal growth factor receptors tyrosine kinase inhibitor lapatinib has been shown to trigger suicidal death or apoptosis of tumor cells and is thus used for the treatment of malignancy. Side effects of lapatinib include anemia, which could, at least in theory, result from stimulation of eryptosis, the suicidal death of erythrocytes which is characterized by cell shrinkage and phospholipid scrambling of the cell membrane leading to phosphatidylserine translocation to the erythrocyte surface. Mechanisms involved in the triggering of eryptosis include oxidative stress, increase of cytosolic Ca²⁺ activity ([Ca²⁺]_i), and ceramide. The present study explored, whether lapatinib induces eryptosis. Methods: Phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, [Ca²⁺]_i from Fluo3-fluorescence, abundance of reactive oxygen species (ROS) from DCFDA dependent fluorescence, and ceramide abundance utilizing labelled specific antibodies. Results: A 48 hours exposure of human erythrocytes to lapatinib (≥ 1 µg/ml) significantly increased the percentage of annexin-V-binding cells, and significantly decreased forward scatter. Lapatinib (7.5 µg/ml) did not significantly modify DCFDA fluorescence and ceramide abundance. Lapatinib slightly, but significantly decreased Fluo3-fluorescence (≥ 5 µg/ml). Lapatinib (7.5 µg/ml) enhanced the annexin-V-binding in the presence of the Ca²⁺ ionophore ionomycin (1 µM) without significantly modifying Fluo3 fluorescence in the presence of ionomycin. The effect of lapatinib on forward scatter but not on annexin-V-binding was significantly blunted by removal of extracellular Ca²⁺. Conclusion: Lapatinib triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect occurring despite decrease of cytosolic Ca²⁺ activity.

show abstract

Lapatinib for treatment of advanced or metastasized breast cancer: systematic review

Cited by 6 publications

References 26 publications

Methodological quality of systematic reviews and clinical trials on women's health published in a Brazilian evidence-based health journal

Methodological quality of systematic reviews and clinical trials on women's health published in a Brazilian evidence-based health journal

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis

Lapatinib Induced Suicidal Death of Human Erythrocytes

Contact Info

Product

Resources

About